Development of an Atmospheric Plasma Applicator to Treat Chronic Wounds

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44GM099207-02
Agency Tracking Number: R44GM099207
Amount: $2,188,490.00
Phase: Phase II
Program: SBIR
Awards Year: 2013
Solicitation Year: 2013
Solicitation Topic Code: NIGMS
Solicitation Number: PA12-088
Small Business Information
ADVANCED PLASMA PRODUCTS, INC.
231 Sam Rayburn Parkway, Lenior City, TN, 37771-
DUNS: 24109418
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 KIMBERLY KELLY-WINTENB
 (865) 317-1425
 kwintenb@advancedplasmaproducts.com
Business Contact
 KIMBERLY WINTENBERG
Phone: (865) 777-3776
Email: kwintenb@advancedplasmaproducts.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): Annually, 5 to 7 million Americans are treated for chronic wounds that arise from diabetes, lower extremity arterial disease, lower extremity venous disease, pressure ulcers, and traumatic injuries, including burns, demonstrating the need for new advanced technologies for treatment. Advanced Plasma Products will build upon its successful Phase I results and advance the development of the Atmospheric Plasma Wound Applicator (APWA) prototypes that inactivate biofilm without causing damage to surrounding tissues, thereby healing the wound. The prototype will be tested for its wound disinfecting capabilities with in vitro wound biofilm models of different clinically significant strains and polymicrobial biofilm. Penetration studies will be performed to evaluate the depth of plasma active species in tissue and mechanistic studies will evaluate the mechanism of inactivation of microbial cells by plasma treatment. We will demonstrate the therapeutic potential of atmospheric plasma to improve wound healing by the removal of microorganisms from the biofilm of splinted excisional wounds of normal and diabetic mice and the introduction of various gaseous nitrogen species. A second generation prototype will be built and tested in a clinical setting with equine lower limb wounds. Following this two year effort, APP will initiate FDA 510K regulatory approval process. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Public Health Impact Statement Chronic wounds affect 5 to 7 million Americans annually and generate healthcare cost in the billions of dollars. More importantly, chronic wounds contribute significantly to the mortality of patients in the United States, and lead to over 80,000 amputations annually due to complicationsin diabetic and peripheral arterial disease patients. Most chronic wounds are treated by outpatients wound care center requiring weekly visits and can take months to years to heal at high costs. The health-related quality of life of patients suffering fromchronic wounds is similar to that of patients wih recurrent cancer. There is an increase in lack of mobility and patients feel isolated and the incidence of depression is significantly higher than the general population. Since many chronic wound patientsare 65 years of age or older and covered by Medicare or Medicaid, there is a push to look at lower-cost alternative treatment technologies. Building upon our expertise in disinfection/sterilization of sensitive items, APP is meeting this demand to effectively treat chronic wounds by developing an Atmospheric Plasma Applicator using its patented atmospheric plasma technology.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government